“A broad and top-notch update on RCC diagnostics and treatment”

22 May 2019

“There is a lot going on in renal cell carcinoma treatment and RCC19 provides an excellent opportunity to get expert views on the recent developments,” says Prof. Marc-Oliver Grimm (Jena, DE). Prof. Grimm is co-chair of the RCC19 Scientific Committee, together with Prof. Axel Bex (London, GB).

“A number of changes are currently underway, regarding various aspects of renal cell carcinoma diagnostics and treatment,” says Grimm. “This starts with the small(er) renal mass, where for instance the role of biopsy and nephron-sparing surgery have been reconsidered a bit. This also refers to metastatic disease where we discuss the role of cytoreductive nephrectomy and get a number of new systemic therapies starting this year.”

RCC19 is taking place in Prague on 7-8 June. Online registration will remain open until May 30th. Registration for RCC19 includes accommodation in Prague for two nights, with many further discounts for EAU(N) members, residents and junior members. The meeting has a strong educational character, with expert faculty in a smaller setting for more interaction than at most other meetings.

Prof. Grimm is the director of the University of Jena’s Urology Clinic. He is also a member of the German Guidelines Groups for Prostate and Bladder Cancers and the Scientific Congress Office of the European Association of Urology. He currently serves on the board of the German Society of Urology.

Prof. Grimm’s major interests are clinical trials for renal, bladder, and prostate cancers, and translational research with a focus on biomarkers in renal cell and non–muscle-invasive bladder cancers.

Pressing topics in RCC

According to Prof. Grimm, a major topic in RCC this year is the advent of immunotherapy in the first line setting of metastatic RCC. “This may also affect the indication for cytoreductive nephrectomy since the CARMENA study, suggesting no benefit of cytoreductive nephrectomy in most cases, was not performed with the upcoming new standard of care treatment with a PD-1 immune checkpoint inhibitor as backbone. I am really looking forward to hear other experts’ views about cytoreductive nephrectomy in this new situation.”

Looking to the coming years, Prof. Grimm sees a responsibility for urologists to be informed on emerging treatment options and their possible side-effects. “Even if urologists in most countries do not administer these kind of therapies – it is important to be informed about efficacy and safety of these drugs.”

“Furthermore, this ‘new immunotherapy’ may be associated with so called immune-related adverse events. Since this therapy is also moving into the perioperative, neoadjuvant and adjuvant setting in renal and bladder cancer, urologists need to be aware of these side effects, how to diagnose and manage these. The EAU believes that this is of paramount importance and will shortly publish a position paper on the multidisciplinary safe use of these drugs.”

Scientific programme

“The meeting will summarise the recent developments on the highest possible level,” says Grimm. “We really have the top experts in the field as speakers to deliver best possible education. The meeting is just one week after the ASCO Annual Meeting so participants will also be informed about the breaking news from there, at least in the metastatic setting.”

“Every urologist who is focused on the field of urooncology can expect a broad and top-notch update when taking part in RCC19. So the meeting is an excellent choice for those still in advanced urology training but also for those already dedicated to urooncology.”